drugset / Trial / NCT00923676

Treatment of Hyperlipidemia and Sexual Dysfunction

NCT00923676

Phase 4 Unknown 300 enrolled University of Campania Luigi Vanvitelli
RandomizedParallel-groupSingle-blindTreatment

Summary

Hyperlipidemias are frequently associated with and are considered an important cause of erectile dysfunction in men. This association has been attributed to the impairment of blood flow through endothelium-dependent relaxation in smooth muscle cells of corpus cavernosum. Basic science and human research suggest that the vascular pathophysiology of male and female sexual dysfunction may be similar, as the first phase of the female sexual response is mediated by a combination of vasocongestive and neuro-muscular event which include increased clitoral length and diameter, as well as increased vaginal lubrication, wall engorgement and luminal diameter. The investigators have shown that women with hyperlipidemia had a higher prevalence of sexual dysfunction as compared with age-matched women without hyperlipidemia. The aim of this study was to asses the effect of anti-hyperlipidemic drugs (fenofibrate and rosuvastatin, single or in combination) on validated indices of sexual function in hyperlipidemic men and women with sexual dysfunction at baseline.

Timeline

Start
2008-04
Primary completion
2015-10
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fenofibrate Small molecule 145 mg
Comparator Rosuvastatin Small molecule 10 mg